Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic livercancer: a phase I trial.

Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH.
Lancet Oncol. 2008 Jun;9(6):533-42.